Hepatitis C Virus
Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy
Published in Healthcare Mergers, Acquisitions and Ventures Week, November 24th, 2007
"The results of the Albuferon non-responder study demonstrated that Albuferon treatment at doses up to 1800 mcg every two weeks had an acceptable long-term safety profile and produced an overall sustained virologic response (SVR) rate of 17% in these patients," said David Nelson, M.D., Associate...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions and Ventures Week
More Articles from Healthcare Mergers, Acquisitions and Ventures Week
- 100 Women in Hedge Funds
100 Women in Hedge Funds Names iMentor Beneficiary of the 2007 New York Gala - 1199SEIU; UFCW; Ilwu
Hundreds of Benefit Fund Trustees Question Viability of Rite Aid Pharmacy Benefit Management Company - 1199SEIU; UFCW; Ilwu
Labor Union Coalition Alerts Industry Analysts About Rite Aid - 1199SEIU; UFCW; Ilwu
Rite Aid's Fledgling Benefits Management Firm Hits Turbulence at Employee Benefits Conference in Anaheim - Abbott
Abbott to Present at Credit Suisse Healthcare Conference - Abdominal Aortic Aneurysm
Endologix to Present at Stephens Inc. Fall Investment Conference - More from this issue of Healthcare Mergers, Acquisitions and Ventures Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
